Investor Presentaiton
FY 2022/23 guidance breakdown: significant negative impact from
input cost increases on EBIT margin
Revenue growth assumptions
FY 2022/23 organic growth expected at
around 8% in constant currencies
• China Ostomy Care and Wound Care - negative
impact from COVID-19 in H1 and improvement in
growth in H2, driven by a lower baseline last year, as
well as the normalisation in hospital access and
procedural volumes
•
US - sustained good momentum in Ostomy Care, and
improvement in growth in Continence Care, driven by
the normalisation of growth in new patients to pre-
COVID levels in H2 21/22
Interventional Urology expected to grow around 10%
Development since issue of FY guidance in
November 2022
Unchanged
Negative
ILLUSTRATIVE
Key impacts on gross- and EBIT margin development in 2022/23 Positive
Gross margin (%)
68.8
GP margin
FY 21/22
Development
in FY 21/22
Assumption
for FY 22/23
쇼
66-67%
Energy
Wages Hungary Currency effect
Atos Medical²
GP margin
FY 22/23
Raw
materials
-55% of COGS
-2% of COGS
9% of COGS¹
Double-digit
price increase
Around 100%
increase
Double-digit
increase
15
•
Voice & Respiratory Care expected to grow 8-10%,
with 8 months impact on organic growth
-3%-pts
8-9%
-8%
Organic
growth 22/23
(Constant
currencies)
--2%-pt
+
Currency
effect
Acquired Reported
growth growth 22/23
30.6
ILLUSTRATIVE
28-29%
EBIT margin (%)
EBIT margin
FY 21/22
Development
in FY 21/22
Assumption
for FY 22/23
GP margin
Leverage
effect/scale
on fixed costs
Atos
amortisation
152mDKK
(8 mths)
~220mDKK
(12 mths)
Currency effect
Incremental
investments
EBIT margin
FY 22/23°
Lower end of
Strive25
guidance level4
1) Direct salaries as % of total COGS. 80% of production volumes are in Hungary. 2) 4 months incremental impact in 2022/23. 3) Before special items.
Special items of DKK 471 million in FY 21/22 and around DKK 50 million expected in FY 2022/23. 4) Strive25 guidance: Investments of up to 2% of sales
in incremental OPEX investments
ColoplastView entire presentation